本帖最后由 肖恩 于 2016-12-19 18:26 编辑
Nivolumab is one of the world’s first immunotherapy drugs and works by cutting the brakes of the immune system so it can fight back against cancer. A trial to see if it worked on young people suffering Hodgkin's lymphoma found that 66 percent of the 80 participants saw their tumors shrink significantly while one in 10 were given the all clear.[size=1.7]“If a patient’s cancer progresses despite available treatment, there is often little that can be done. “For the first time in this very sick patient group we are seeing immunotherapy treatment considerably reduce cancer burden in a majority of patients. “Nivolumab is now offering real promise in this disease. The hope is that this will translate into longer survival in more patients than has been possible to date.” pd-1是目前為數不多的免疫抗癌藥物。通過阻止抑制t 細胞的免疫機制生效,pd-1使得t細胞能被動員起來攻擊體內的癌細胞。在最近的一個80人參與的臨床實驗中,pd-1對66%的復發難治霍奇金淋巴瘤患者有效。其中10%的患者達到了完全緩解。在此以前,如果霍奇金淋巴瘤對一線abvd化療和二線化療都不敏感的話,預後不理想。原發耐藥的5年生存率約為26%。pd-1使不少病危病重的霍奇金患者再次達到了緩解。再不久的將來,pd-1的廣泛應用將極大地改善這一組病人的預後。 補充:總體而言,i-ii期霍奇金的5年生存率高達90%以上,是預後最佳的癌症之一 iii-iv期的5年生存率亦在70%-90%之間
|